$Vir Biotechnology(VIR.US)$They need better cost control and accounting practice to boost share price to a reasonable level (say 20). Section is bad because of Biden, but literally science is priced at 0 for VIR. Active investor should interfere. I’ll vote all Against in proxy, as I am not happy at all.
$Vir Biotechnology(VIR.US)$small scale experiments are good. no idea why they issue cost guidance (huge) without revenue guidance. Stupid. I don’t like new management goes back to clinical stage biotech. They hire too many people and relocate position to high salary area. AI expert in San Francisco, come on… If not sotrovimab and help of GSK made huge money, this company would have doomed.(if not stopped by Biden, would have been 40 dollar per share). I’ll start...
Morning Movers Gapping up $ZoomInfo(ZI.US)$The software stock popped 5.5% after Bank of America analyst Koji Ikeda upgraded it to buy from neutral. “We believe it is a classic self-help story that is set to outperform,” the analyst wrote, underscoring the company’s revenue growth reacceleration and new AI products as potential catalysts. $波音(BA.US)$stock rose 0.9% after Ryanair, Europe's largest airline by passenger number...
The multiple insider sales in Vir Biotechnology and zero buying activity in the last year may be a concern for potential investors. However, a fair level of insider ownership suggests a reasonable alignment of interests with shareholders.
Adobe's stock fall and FTC probe may hit future results. Pfizer's reduced earnings projection could reshape investor outlook. Vir Biotechnology's austerity measures aim at fiscal stability. Nordson's weak Q1 forecast may impact near-term stocks.
$Vir Biotechnology(VIR.US)$so stupid action. Already bought too heavy position. can only average down to 25.5. I have confidence this is a 20 to 30 dollar stock at least.
Vir Biotechnology股票讨论区
I think CFO is actually fired.
good earnings but i don’t like
no idea why they issue cost guidance (huge) without revenue guidance. Stupid.
I don’t like new management goes back to clinical stage biotech. They hire too many people and relocate position to high salary area. AI expert in San Francisco, come on… If not sotrovimab and help of GSK made huge money, this company would have doomed.(if not stopped by Biden, would have been 40 dollar per share). I’ll start...
专栏Today's Morning Movers and Top Ratings: MSFT, ZI, AAL, HSY and More
Gapping up
$ZoomInfo(ZI.US)$ The software stock popped 5.5% after Bank of America analyst Koji Ikeda upgraded it to buy from neutral. “We believe it is a classic self-help story that is set to outperform,” the analyst wrote, underscoring the company’s revenue growth reacceleration and new AI products as potential catalysts.
$波音(BA.US)$ stock rose 0.9% after Ryanair, Europe's largest airline by passenger number...
Upcoming Ph 2 readouts in Q1 2024…
$Regenxbio(RGNX.US)$ Phase 2
$Leap Therapeutics(LPTX.US)$ Phase 2
$4D Molecular Therapeutics(FDMT.US)$ Phase 2
$Adverum Biotechnologies(ADVM.US)$ Phase 2
$Denali Therapeutics(DNLI.US)$ Phase 2
$EyePoint Pharmaceuticals(EYPT.US)$ Phase 2
$Xencor(XNCR.US)$ Phase 2
$Harmony Biosciences(HRMY.US)$ Phase 2
$阿里拉姆制药(ALNY.US)$ Phase 2
$Disc Medicine(IRON.US)$ Phase 2
$Atea Pharmaceuticals(AVIR.US)$ Phase 2
$Allakos(ALLK.US)$ Phase 2...
做财报会议了总不是坏事
新增数据:2022四季度及全年报,2023Q1
2022年4季度营收萎缩93.9%到0.49亿,营业利润均转亏,2023Q1营收萎缩94.9%到0.63亿,营业利润和净利润继续亏损。
目前公司净资产19.7亿,刨掉3.1亿非流动资产还有16.6亿,目前看一年亏损大约6亿,这笔钱大约够亏3年,目前仓位不重,暂时持仓观望。
bottom confirms
I have confidence this is a 20 to 30 dollar stock at least.
暂无评论